IR Stock Analysis: Ingersoll Rand | NYSE
Specialty Industrial Machinery | NYSE, USA | Market Cap: 29.143m USD | 12M Return: -9.8% | US45687V1061 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 339M
EPS Trend: 83.2%
Qual. Beats: 0
Rev. Trend: 99.2%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 9.4 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Ingersoll Rand Inc. (NYSE: IR) is a global provider of mission-critical air, fluid, clean energy, and medical technologies, operating through two main segments: Industrial Technologies and Services, and Precision and Science Technologies. The Industrial segment focuses on compressors, vacuum and blower products, fluid transfer equipment, loading systems, and power tools, while the Precision and Science Technologies segment manufactures pumps, gas boosters, hydrogen compression systems, and liquid handling solutions for medical, laboratory, industrial, water and wastewater, chemical processing, clean energy, food and beverage, and agricultural applications.
The company sells its products under a wide portfolio of well-established brands, including Gardner Denver, Nash, CompAir, Elmo Rietschle, ARO, Haskel, Milton Roy, Thomas, Welch, and Seepex, among others. Distribution is conducted through a combination of direct sales representatives and independent distributors, and the company maintains a strategic alliance with Garrett Motion. As a Large Cap industrial machinery company headquartered in Davidson, North Carolina, Ingersoll Rand was founded in 1859 and was formerly known as Gardner Denver Holdings, Inc. before adopting its current name in March 2020.
- orders track global manufacturing PMI cycle
- Aftermarket services revenue mix expands operating margins
- Bolt-on acquisitions accelerate growth in precision fluid handling
| Net Income: 959.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -0.49 > 1.0 |
| NWC/Revenue: 20.58% < 20% (prev 31.99%; Δ -11.41% < -1%) |
| CFO/TA 0.07 > 3% & CFO 1.35b > Net Income 959.1m |
| Net Debt (3.74b) to EBITDA (1.97b): 1.89 < 3 |
| Current Ratio: 1.62 > 1.5 & < 3 |
| Outstanding Shares: last quarter (392.0m) vs 12m ago -2.11% < -2% |
| Gross Margin: 37.94% > 18% (prev 43.74%; Δ -5.79% > 0.5%) |
| Asset Turnover: 43.82% > 50% (prev 40.78%; Δ 3.04% > 0%) |
| Interest Coverage Ratio: 5.70 > 6 (EBIT TTM 1.47b / Interest Expense TTM 257.1m) |
| A: 0.09 (Total Current Assets 4.29b - Total Current Liabilities 2.65b) / Total Assets 18.2b |
| B: 0.19 (Retained Earnings 3.49b / Total Assets 18.2b) |
| C: 0.08 (EBIT TTM 1.47b / Avg Total Assets 18.1b) |
| D: 1.28 (Book Value of Equity 10.2b / Total Liabilities 7.95b) |
| Altman-Z'' = 3.10 = A |
| DSRI: 1.01 (Receivables 1.51b/1.39b, Revenue 7.94b/7.36b) |
| GMI: 1.15 (GM 43.74% / 37.94%) |
| AQI: 0.99 (AQ_t 0.71 / AQ_t-1 0.72) |
| SGI: 1.08 (Revenue 7.94b / 7.36b) |
| TATA: -0.02 (NI 959.1m - CFO 1.35b) / TA 18.2b) |
| Beneish M = -2.83 (Cap -4..+1) = A |
As of October 02, 2026, the stock is trading at USD 75.25 with a total of 5,424,781 shares traded. Over the past week, the price has changed by +0.63%, over one month by +0.82%, over three months by -6.92% and over the past year by -9.79%.
Current recommended Stop Loss: 72.60 (which is 3.5% or 1.3 ATR below the current price).
Ingersoll Rand has received a consensus analysts rating of 3.94. Therefore, it is recommended to buy IR.
- StrongBuy: 7
- Buy: 2
- Hold: 8
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 94.7 | 25.9% |
P/E Trailing = 31.692
P/E Forward = 19.3424
P/S = 3.6693
P/B = 2.9058
P/EG = 0.6181
Revenue TTM = 7.94b USD
EBIT TTM = 1.47b USD
EBITDA TTM = 1.97b USD
Long Term Debt = 4.06b USD (from longTermDebt, last quarter)
Short Term Debt = 764.1m USD (from shortTermDebt, last quarter)
Debt = 4.91b USD (from shortLongTermDebtTotal, last quarter) + Leases 76.3m
Net Debt = 3.74b USD (calculated: Debt 4.91b - CCE 1.17b)
Enterprise Value = 32.9b USD (29.1b + Debt 4.91b - CCE 1.17b)
Interest Coverage Ratio = 5.70 (Ebit TTM 1.47b / Interest Expense TTM 257.1m)
EV/FCF = 26.96x (Enterprise Value 32.9b / FCF TTM 1.22b)
FCF Yield = 3.71% (FCF TTM 1.22b / Enterprise Value 32.9b)
FCF Margin = 15.35% (FCF TTM 1.22b / Revenue TTM 7.94b)
Net Margin = 12.08% (Net Income TTM 959.1m / Revenue TTM 7.94b)
Gross Margin = 37.94% ((Revenue TTM 7.94b - Cost of Revenue TTM 4.93b) / Revenue TTM)
Gross Margin QoQ = 42.10% (prev 42.90%)
Tobins Q-Ratio = 1.81 (Enterprise Value 32.9b / Total Assets 18.2b)
Interest Expense / Debt = 5.24% (Interest Expense 257.1m / Debt 4.91b)
Taxrate = 20.24% (245.1m / 1.21b)
NOPAT = 1.17b (EBIT 1.47b * (1 - 20.24%))
Current Ratio = 1.62 (Total Current Assets 4.29b / Total Current Liabilities 2.65b)
Debt / Equity = 0.48 (Debt 4.91b / totalStockholderEquity, last quarter 10.2b)
Debt / EBITDA = 1.89 (Net Debt 3.74b / EBITDA 1.97b)
Debt / FCF = 3.06 (Net Debt 3.74b / FCF TTM 1.22b)
Total Stockholder Equity = 10.1b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.29% (Net Income 959.1m / Total Assets 18.2b)
RoE = 9.46% (Net Income TTM 959.1m / Total Stockholder Equity 10.1b)
RoCE = 10.33% (EBIT 1.47b / Capital Employed (Equity 10.1b + L.T.Debt 4.06b))
RoIC = 7.35% (NOPAT 1.17b / Invested Capital 15.9b)
WACC = 9.07% (E(29.1b)/V(34.1b) * Re(9.89%) + D(4.91b)/V(34.1b) * Rd(5.24%) * (1-Tc(0.20)))
Discount Rate = 9.89% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -93.94 | Cagr: -1.78%
[DCF] Terminal Value 72.03% ; FCFF base≈1.25b ; Y1≈1.19b ; Y5≈1.14b
[DCF] Fair Price = 31.53 (EV 16.0b - Net Debt 3.74b = Equity 12.2b / Shares 388.0m; r=9.07% [WACC]; 5y FCF grow -6.08% → 2.50% )
EPS Correlation: 83.20 | EPS CAGR: 5.32% | SUE: 0.71 | # QB: 0
Revenue Correlation: 99.20 | Revenue CAGR: 5.92% | SUE: 3.60 | # QB: 1
EPS current Quarter (2026-09-30): EPS=0.90 | Chg30d=-0.13% | Revisions=-31% | Analysts=12
EPS current Year (2026-12-31): EPS=3.55 | Chg30d=-0.06% | Revisions=+82% | GrowthEPS=+6.4% | GrowthRev=+6.1%
EPS next Year (2027-12-31): EPS=3.92 | Chg30d=+0.05% | Revisions=+64% | GrowthEPS=+10.3% | GrowthRev=+5.0%
[Analyst] Revisions Ratio: +50% (up=27, down=8)